Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**S-3304 + paclitaxel + carboplatin** is an investigational three-drug combination regimen, where S-3304 is a matrix metalloproteinase inhibitor used alongside chemotherapy agents paclitaxel and carboplatin. Paclitaxel is a microtubule stabilizer that inhibits cell division by promoting tubulin polymerization and arresting mitosis, while carboplatin is a platinum-based DNA alkylating agent leading to apoptosis through DNA crosslinking. This combination is explored as a potential antineoplastic approach, targeting tumor invasion and metastasis by blocking matrix degradation (S-3304) and cytotoxicity to malignant cells (paclitaxel, carboplatin).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on S-3304 + paclitaxel + carboplatin.